Funding for this research was provided by:
the Korea Health Technology R&D Project through the Korea Health Industry Development Institute (KHIDI), funded by the Ministry of Health & Welfare, Republic of Korea (HI16C0287)
the Basic Science Research Program through the National Research Foundation (NRF) of Korea funded by the Ministry of Education (2017R1A2B2001881)
Hallym University research fund
Received: 5 March 2020
Accepted: 15 September 2020
First Online: 29 September 2020
Ethics approval and consent to participate
: The HAS study and KNHANES study were approved by the institutional review board of the Hallym University School of Medicine (IRB approval number: HIRB-2007-001) and by the Korea Centers for Disease Control and Prevention institutional review board in Korea (2010-02CON-21-C, 2011-02CON-06-C and 2012-01EXP-01-2C), respectively. Both study protocols conformed to the ethical guidelines of the 1975 Declaration of Helsinki and written informed consent was obtained from each participant.
: Not applicable.
: The authors declare that they have no competing interests. The OAI is a public-private partnership comprised of five contracts funded by the National Institutes of Health. Private funding partners include Merck Research Laboratories; Novartis Pharmaceuticals Corporation, GlaxoSmithKline; and Pfizer, Inc.